A 2026 anal squamous cell carcinoma strategy report covering HPV burden, PD-1 and EGFR biology, clinical competition, deal signals and portfolio positioning.

A 2026 testicular germ cell tumor strategy report covering young-adult burden, KIT and PARP1 biology, clinical competition, deals and portfolio positioning.

A 2026 thymic carcinoma strategy report covering disease burden, KIT and PD-1 biology, clinical competition, deal signals and portfolio positioning.

A 2026 malignant mesothelioma strategy report covering asbestos burden, mesothelin and BAP1 biology, clinical competition, deal signals and portfolio positioning.

A 2026 retinoblastoma strategy report covering childhood burden, MDM2 and E2F1 biology, clinical competition, deal activity and portfolio positioning.

A 2026 neuroblastoma strategy report covering childhood burden, GD2 and ALK biology, clinical competition, deal activity and portfolio positioning.

A 2026 Ewing sarcoma strategy report covering adolescent burden, EWSR1 and CD99 biology, clinical competition, deal signals and portfolio positioning.

Aurinia Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

ESSA Pharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

ProMIS Neurosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Karuna Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Cerevel Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.